Merck & Co., Inc. vs Upwork Inc — how do they compare? Merck & Co., Inc. trades at $132.93 (market cap $321.77B), while Upwork Inc trades at $8.31 (market cap $1.04B). The key difference: Merck & Co., Inc. is far larger — about 309.4× Upwork Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Upwork Inc pays none. Which is the better fit depends on your goals.
| MRK | UPWK | |
|---|---|---|
Market Cap | $321.77B | $1.04B |
Sector | Health | Industrials |
52-Week High | $131.84 | $22.11 |
52-Week Low | $77.60 | $7.84 |
Enterprise Value | $368.53B | $806.15M |
Dividend Yield | 2.61% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue reached $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, supported by analyst consensus favoring a buy rating (67.57%) and a price target of $140.36. Key opportunities include pipeline expansion through M&A and solid cash flow generation. Risks involve high valuation multiples, such as a P/E of 104.34, and potential integration challenges from acquisitions. Investors should weigh growth prospects against elevated earnings expectations and market volatility.
Upwork (UPWK) stock is trading at $8.385, down 14.7% on the day following Q2 2026 results. While the company beat earnings expectations with EPS of $0.41 versus $0.3424, weak forward guidance triggered the sell-off. The stock exhibits a bearish technical signal, trading near key support levels. Fundamentally, the company maintains solid profitability metrics, including a 77.21% gross margin and a P/E ratio of 10.71, but faces headwinds from declining active client counts and AI-related market shifts.
The outlook is cautious. Analyst consensus remains a 'Buy' with a $9.25 price target, suggesting potential upside from current levels. However, near-term risks are elevated due to the guidance miss, ongoing client attrition, and potential legal investigations. The stock's valuation appears reasonable, but investor confidence hinges on the company's ability to stabilize client growth and navigate the AI disruption in the freelance market.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →